DAX24.875 +0,3%Est505.992 +0,2%MSCI World4.343 -0,1%Top 10 Crypto8,6400 -0,1%Nas22.472 -0,3%Bitcoin56.946 -2,1%Euro1,1814 -0,3%Öl66,90 -2,5%Gold4.880 -2,3%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 SAP 716460 Siemens 723610 Deutsche Telekom 555750 Siemens Energy ENER6Y NVIDIA 918422 Amazon 906866 Bayer BAY001 Lufthansa 823212 Microsoft 870747 DroneShield A2DMAA BASF BASF11 RENK RENK73 Mercedes-Benz Group (ex Daimler) 710000 Deutsche Bank 514000
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Dow schwächer -- DAX fester -- Novo Nordisk setzt Aktienrückkauf fort -- Rheinmetall mit Großauftrag -- Steyr, Microsoft, TeamViewer, Norwegian, BHP, Ottobock, Warner Bros. im Fokus
Top News
Tesla-Aktie im Fokus: Staatsanwaltschaft ermittelt nach Anzeige wegen Mitschnitts in Grünheide Tesla-Aktie im Fokus: Staatsanwaltschaft ermittelt nach Anzeige wegen Mitschnitts in Grünheide
Chevron-Aktie schwächer: Gas-Erkundung vor Kreta und Peloponnes gestartet Chevron-Aktie schwächer: Gas-Erkundung vor Kreta und Peloponnes gestartet
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Wer­bung
Unser ETF-Compass 2026: Die wichtigsten Trends für ETF-Anleger in diesem Jahr. Hier geht's zur Übersicht.

AbCellera Biologics Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
2,59 EUR -0,05 EUR -1,71 %
STU
3,08 USD -0,04 USD -1,12 %
BTT
AbCellera Biologics jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.783,33 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA2QKXS

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINCA00288U1066

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolABCL

AbCellera Biologics Aktien News

DatumMeistgelesen
BusinesswireAbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology
BusinesswireAbCellera to Present at Upcoming Investor Conferences in December and January
BusinesswireAbCellera Reports Q3 2024 Business Results
Wer­bungAbCellera Biologics-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
BusinesswireAbCellera to Present at Upcoming Investor Conferences in November 2024
BusinesswireAbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024
BusinesswireAbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024
BusinesswireAbCellera to Present at Upcoming Investor Conferences in September
BusinesswireAbCellera Reports Q2 2024 Business Results
BusinesswireAbCellera and Lilly Expand Collaboration to Develop Antibody Medicines
BusinesswireAbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024
BusinesswireAbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024
BusinesswireAbCellera Reports Q1 2024 Business Results
BusinesswireAbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies
BusinesswireAbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024
BusinesswireAbCellera to Report First Quarter 2024 Financial Results on May 7, 2024
BusinesswireAbCellera to Present at the Piper Sandler 35th Annual Healthcare Conference on November 30, 2023
BusinesswireAbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023
BusinesswireAbCellera Reports Q3 2023 Business Results
BusinesswirePrelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
BusinesswireAbCellera to Present at the Jefferies London Healthcare Conference on November 14, 2023
BusinesswireAbCellera to Report Third Quarter 2023 Financial Results on November 2, 2023
BusinesswireAbCellera Announces Two T-Cell Engager Presentations at SITC 2023
BusinesswireAbCellera Expands Multi-Target Antibody Discovery Collaboration with Regeneron
BusinesswireAbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology
BusinesswireAbCellera Announces that the U.S. Patent Trial and Appeal Board Has Denied Berkeley Lights’ Request for Rehearing
BusinesswireAbCellera to Report Second Quarter 2023 Financial Results on August 3, 2023
BusinesswireAbCellera to Present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023
BusinesswireAbCellera Partners with the Governments of Canada and British Columbia to Advance Drug Development Capabilities and Infrastructure that Will Accelerate Innovative Medicines to Patients
BusinesswireAbCellera Reports Q1 2023 Business Results
BusinesswireAbCellera Presents New Data on T-Cell Engager Platform at AACR 2023
BusinesswireAbCellera to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference on April 25, 2023
BusinesswireAbCellera to Report First Quarter 2023 Financial Results on May 4, 2023
BusinesswireAbCellera and RQ Bio Partner to Accelerate the Advancement of New Therapies for Infectious Disease
BusinesswireAbCellera Announces Two Presentations on T-Cell Engager Discovery at AACR 2023
BusinesswireAbCellera to Present at the Cowen 43rd Annual Health Care Conference on March 6, 2023
BusinesswireAbCellera Reports Full Year 2022 Business Results

AbCellera Biologics News

AbCellera Biologics News: auf dieser Seite finden Sie alle AbCellera Biologics News und Nachrichten zur AbCellera Biologics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch AbCellera Biologics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um AbCellera Biologics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.